021-51111890
购物车（）
sales@molnova.cn
Dofequidar
CAS No. 129716-58-1
Dofequidar ( MS-209 )
产品货号. M11198 CAS No. 129716-58-1
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥7857 | 有现货 |
|
| 50MG | ￥16038 | 有现货 |
|
| 100MG | ￥20250 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Dofequidar
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
-
产品描述A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR; completely reverses resistance against vincristine in vitro in multidrug-resistant variants of mouse leukemia P388 cells and human leukemia K562 cells at 1-10 uM; greatly reduces the SP-derived tumor growth in vivo combined with CPT-11.Breast cancer Phase 2 Discontinued
-
同义词MS-209
-
通路Membrane Transporter/Ion Channel
-
靶点P-glycoprotein
-
受体P-glycoprotein
-
研究领域Cancer
-
适应症Breast Cancer
化学信息
-
CAS Number129716-58-1
-
分子量481.59
-
分子式C30H31N3O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESC1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5
-
化学全称Ethanone, 1-[4-[2-hydroxy-3-(5-quinolinyloxy)propyl]-1-piperazinyl]-2,2-diphenyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Nakanishi O, et al. Oncol Res. 1997;9(2):61-9.
2. Sato W, et al. Cancer Chemother Pharmacol. 1995;35(4):271-7.
3. Katayama R, et al. Cancer Sci. 2009 Nov;100(11):2060-8.
2. Sato W, et al. Cancer Chemother Pharmacol. 1995;35(4):271-7.
3. Katayama R, et al. Cancer Sci. 2009 Nov;100(11):2060-8.
产品手册
关联产品
-
Tariquidar methanesu...
A potent, specific P-gp inhibitor with Kd of 5.1 nM.
-
Dofequidar fumarate
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
-
Elacridar
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
